Formosa Laboratories Executive and Leadership Team

Chih-Ping Yang, the Chief Executive Officer at Formosa Laboratories, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of GMP-compliant manufacturing processes, the Chief Executive Officer ensures alignment with international regulatory standards set by the US FDA, EDQM, and PMDA. This leadership role involves driving the development of Vitamin D derivatives and specialty chemicals to maintain a competitive edge in the global pharmaceutical market. By fostering partnerships with international health authorities, Chih-Ping Yang secures the company's reputation as a premier producer of APIs and UV-filters. The Chief Executive Officer manages the expansion of custom synthesis services, ensuring that process development meets the complex needs of global clients. Through strategic oversight of production facilities, Yang guarantees operational efficiency and consistent quality across all product lines, ultimately strengthening the market position of the firm within the pharmaceutical manufacturing sector.

C.Y. Cheng, the President at Formosa Laboratories, manages the internal operational workflows and technical infrastructure required for large-scale API production. Focusing on the synthesis of complex compounds like Sevelamer and Montelukast, the President optimizes manufacturing throughput to meet global demand. This role involves coordinating with quality control departments to uphold the strict compliance standards mandated by the DOH of Taiwan and German BGV. By streamlining the transition from process development to full commercial production, C.Y. Cheng ensures that custom synthesis projects achieve timely delivery for international partners. The President monitors the performance of modern facilities to maintain high output levels for UV-filters such as avobenzone. Through rigorous management of technical resources, Cheng supports the company's mission to provide reliable chemical solutions. The President drives operational excellence by implementing advanced production methodologies that enhance the overall efficiency of the manufacturing pipeline.

Chen-Yu Cheng, the President at Formosa Laboratories, oversees the strategic expansion of the company's custom synthesis services and specialty chemical portfolio. By architecting business development initiatives, the President identifies new market opportunities for APIs like Gadodiamide and Mycophenolate Mofetil. This leadership role involves managing the documentation support systems necessary for global regulatory filings, ensuring that all products meet the stringent requirements of international health agencies. Chen-Yu Cheng directs the cross-functional teams responsible for scaling production capabilities to accommodate diverse client specifications. Through the cultivation of strong relationships with global pharmaceutical partners, the President expands the reach of the company's UV-filter and API offerings. The President focuses on enhancing the value proposition of custom synthesis by providing comprehensive technical support from initial development to final commercialization. Ultimately, Cheng drives revenue growth by aligning production capacity with the evolving needs of the global pharmaceutical industry.

C.P. Yang, the President at Formosa Laboratories, leads the strategic initiatives focused on supply chain optimization and the procurement of raw materials for API manufacturing. Overseeing the logistics of distributing products like Balsalazide and Benzonatate, the President ensures that the company maintains a robust presence in international markets. This role involves collaborating with the Board to allocate resources toward facility upgrades and technological advancements in chemical synthesis. By managing the complexities of global distribution, C.P. Yang guarantees that the company meets the high-volume requirements of international clients while adhering to strict GMP compliance. The President monitors market trends to adjust production schedules for products such as Octinoxate, ensuring that supply remains consistent with demand. Through the implementation of efficient inventory management systems, C.P. Yang supports the company's goal of providing reliable, high-quality pharmaceutical ingredients to the global healthcare sector, thereby maintaining a competitive advantage.